Skip to main content
Back
Watch Compare

Mosaic ImmunoEngineering Inc.

Data quality: 83%
CPMV
OTC Manufacturing Chemicals
$0.70
$0.00 (0.00%)
6 months return
—
Momentum
Neutral
Free cash flow
-103,975.0

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.01
Interest Coverage-58.96

Valuation

PE (TTM)
-8.03
Below sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -103,975.0

Price History

Financial Trends

Analyst Price Target

No analyst coverage available

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -671,753.0
ROE N/A ROA -1188.97%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -103,975.0
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0.01
Debt / Equity N/A Current Ratio 0.01
Interest Coverage -58.96 Asset Turnover N/A
Working Capital -5.86 M Tangible Book Value -7.31 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -8.03 · EV/EBITDA: N/A
P/E Ratio -8.03 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1.93%
Market Cap 5.40 M Enterprise Value 5.36 M

Per Share

EPS: -0.09 · FCF/Share: -0.01
EPS (Diluted TTM) -0.09 Revenue / Share N/A
FCF / Share -0.01 OCF / Share -0.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 15.48% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 15.48%
SBC-Adj. FCF -103,975 Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — — —
Net Income -921,983.0 -1.01 M -2.38 M -3.68 M -842,243.0
EPS (Diluted) -0.13 -0.14 -0.33 -0.55 -1.12
Gross Profit — — — — —
Operating Income -879,655.0 -1.40 M -2.63 M — —
EBITDA — — — — —
R&D Expenses 183,867.0 435,449.0 1.05 M 1.46 M 342,727.0
SG&A Expenses — — — — 996,019.0
D&A — — — — —
Interest Expense 6,954.0 — — — —
Income Tax 2,400.0 2,400.0 2,400.0 2,400.0 1,600.0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 141,611.0 179,533.0 261,277.0 269,494.0 457,802.0
Total Liabilities 6.93 M 6.05 M 5.15 M 3.07 M 880,343.0
Shareholders' Equity -6.79 M -5.87 M -4.88 M -2.80 M -422,541.0
Total Debt — — — — —
Cash & Equivalents 115,019.0 156,178.0 220,645.0 226,142.0 352,738.0
Current Assets 141,611.0 179,533.0 261,277.0 269,494.0 457,802.0
Current Liabilities 5.54 M 4.73 M 3.92 M 2.33 M 880,343.0

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -8.0 -1.5
P/B — 1.6
ROE % — -54.7
Net Margin % — -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3